Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

- PMLiVE

EU approval for Takeda’s schizophrenia drug

Latuda said to have improved side effect profile compared to other treatments

- PMLiVE

GSK halts bid for Votrient maintenance use

Pulls European application for indication in advanced ovarian cancer

- PMLiVE

GSK invests in African research and manufacturing

Boosts R&D for non-communicable diseases

Novartis day

Novartis’ dual-action heart failure drug aces trial

Ends LCZ696 trial early on good results

Novartis building

FDA panel rejects Novartis’ heart failure hope serelaxin

Decision follows EMA knock back earlier this year

- PMLiVE

Baxter splits in two, spinning off biotech business

The 'new' Baxter will focus on medical products

- PMLiVE

EMA clears GSK’s diabetes therapy Eperzan

Once-weekly GLP-1 therapy will line-up against Victoza and Byetta

- PMLiVE

GSK withdraws melanoma combo in EU

EMA says it needs more data to review Mekinist and Tafinlar

Novartis building

More bad news for Novartis on heart failure candidate

FDA reviewers recommend against approving serelaxin

Novartis day

Novartis’ German poster campaign to raise vaccination awareness

In-house designed work aims to educate public about meningococcal bacteria

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Celgene gets FDA OK for first oral psoriatic arthritis drug

Otezla wins US approval to treat the auto-immune disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links